Clinical perspective
MRGPRX2 Reveals New Insights Into Mast Cell Activation in Chronic Urticaria
Mast cell activation plays a central role in chronic urticaria, contributing to the release of inflammatory mediators responsible for hives, itching, and angioedema. While immunoglobulin E (IgE)-dependent pathways have traditionally received considerable attention, emerging research suggests that additional mechanisms may contribute to persistent symptoms. A 2026 review published in Allergologie Select examines the Mas-related G protein-coupled receptor X2 (MRGPRX2) and its potential role in non-IgE-mediated mast cell activation, offering new perspectives on the biological complexity of chronic urticaria.
MRGPRX2 is a receptor expressed predominantly on mast cells that can respond to a variety of substances, including neuropeptides, certain medications, and other positively charged compounds. Unlike the classical IgE-dependent pathway, MRGPRX2 can initiate mast cell degranulation through G protein-coupled signaling. This process leads to the release of inflammatory mediators that contribute to vascular changes, sensory nerve activation, and symptoms associated with urticaria. The receptor's ability to respond to multiple types of stimuli has made it an important area of investigation in inflammatory skin disease.
The review also explores the relationship between MRGPRX2 signaling and neuroimmune interactions. Neuropeptides such as substance P may activate the receptor and contribute to communication between sensory nerves and mast cells. This interaction could help sustain cycles of itching and inflammation in some patients. Researchers have reported increased MRGPRX2 expression and changes in associated signaling molecules in chronic urticaria, suggesting that this pathway may contribute to disease activity in certain clinical presentations.
These findings may have implications for understanding why some patients experience inadequate responses to conventional treatment. Although antihistamines and other established therapies can improve symptoms, they may not address every mechanism involved in mast cell activation. Investigating MRGPRX2 could help researchers identify additional therapeutic targets and potential markers of disease activity. However, much of the evidence remains mechanistic or exploratory, and the clinical significance of targeting this receptor in chronic urticaria requires further investigation.
The growing understanding of MRGPRX2 reinforces the importance of looking beyond traditional IgE-mediated pathways when studying chronic urticaria. As research continues, a more detailed understanding of mast cell signaling and neuroimmune interactions may support the development of new diagnostic and therapeutic strategies. For healthcare professionals, these findings provide additional insight into the biological diversity of chronic urticaria and the scientific questions shaping future treatment research.
Original research: Wu K, Liu J. The MRGPRX2 Paradigm Shift: Redefining Mast Cell Activation Pathways in Chronic Urticaria. Allergologie Select. 2026.